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Abstract
Background
Blood transfusion is considered a potential risk factor for transmission of life-threatening
viral infections, including HIV, HCV and HBV infections. This study was performed to find
out the prevalence and trends of these infections among blood donors in Southern Iran.
Methods
The blood donor data recorded in twelve regional blood transfusion centers from 2004 to
2014 were analyzed in an anonymous way with respect to the results of serological screen-
ing for HBV, HCV, and HIV infections. Overall, 293454 donors were screened for viral
infections.
Results
Most of the donors were male, married, aged between 20–40 years, educated, and regular
donors. The overall seroprevalence rates of HBV, HCV and HIV were 0.15%, 0.1% and
0.004%, respectively. The highest seroprevalence was found for HBV, followed by HCV
and HIV. These infections were more prevalent in male, low educated and first time donors.
The highest HCV seroprevalence was observed among donors aged 20 to 40 years, while
HBV seroprevalence increased with age. The seroprevalence rates of HBV and HCV from
2004 to 2014 showed significant decreasing trends from 0.460% to 0.060% (P < 0.001) and
0.329% to 0.045% (P < 0.001), respectively. Whereas HIV infection had a slight but not sig-
nificant decline from 0.0173% in 2004 to 0.0028% in 2014 (P = 0.087).
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Conclusions
The decreasing trends of transfusion-transmissible viral infections in blood donations indi-
cate that the attempts of IBTO were successful in improving the safety of the blood supply,
since the prevalence rates of viral infections have been reduced to very low levels in blood
donations over the years. However, still more effective techniques such as polymerase
chain reaction (PCR) are needed to guarantee blood safety.
Introduction
The aim of blood transfusion is protection of life, but at the same time, it can be life threatening
if blood safety is not considered [1, 2]. One of the main problems in providing safe blood is the
risk of transfusion-transmissible infections (TTIs). Amongst them, viral infectious agents such
as hepatitis C virus (HCV), hepatitis B virus (HBV) and human immunodeficiency virus
(HIV) are of the greatest concern [1, 3–5].
HIV, HBV and HCV are the causative agents of acquired immune deficiency syndrome
(AIDS), hepatitis B and C infections, respectively. These infections are capable of causing long-
term carrier states, prolonged viraemia and infectivity, chronic disorders along with high rates
of morbidity and mortality due to chronicity, liver cirrhosis, hepatocellular carcinoma (HCC),
and opportunistic infections [3, 4, 6, 7]. These viruses can be transmitted through direct expo-
sure to infected blood and blood derivatives, organ transplantation, hemodialysis, intravenous
drug use, blood transfusion, tattooing, and sexual contact [4, 6, 8]. However, the later is not the
common mode of HCV transmission [8, 9].
The risk of transmission of these viruses through transfusion of infected blood is much
higher than the other routes of transmission, mainly because of transmission of high viral load
per transfusion [3]. Even if the viral load is low in the blood, the chance of infectivity is still
very high [3]. However, currently blood transfusion has a relatively low contribution in the
overall transmission of viral infections owing to this obligation that screening of blood dona-
tions for viral infections prior to transfusion is the highest priority [10].
The prevalence of these viral infections among blood donors varies by geography and
nationality and directly depends on the prevalence of these viruses in the general population
[11, 12]. Globally, there are approximately 170 million individuals chronically infected with
HCV, 350 million with HBV, and 38 million HIV infected people [13]. According to WHO
reports, the prevalence of HBV, HCV and HIV infections among blood donors in different
parts of the world varies from 0.008% to 6.08%, 0.004% to 1.96%, and 0.0004% to 2.0%, respec-
tively [14]. In Iran, the prevalence of HBV, HIV and HCV infections is 1.7% [15], 0.023% [8]
and less than 1% [9] in the general population and 0.7% [16], 0.004% [8] and 0.5% [17] in
blood donors, respectively.
The prevalence of any infection shows a wide range of variation in different regions of a
country [9]. However, the overall prevalence of HCV among blood donors in Iran has been
reported to be 0.5%, but it ranges from 0.03% to 2.1% in different parts of the country [9]. The
same scenario has been reported for HBV [16]. Apart from this, the prevalence rates may
change with time [2]. Variations in the donor screening strategies and the predominance of
risk factors in the society might explain these changes in the prevalence rates of viral infection
over time [9, 18, 19]. It is therefore necessary to assess the prevalence of these viruses among
blood donors at regular intervals to estimate the current most prevalent risk factors and to eval-
uate the effectiveness of the blood safety strategies employed in the blood banks of a country
[17, 19, 20].
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Evaluation of trends in the prevalence of viral infections among blood donors is not only
essential for estimating the effectiveness of the blood safety strategies [8, 18–20], but it also
gives clue to health policy makers to improve the current blood bank strategies to minimize the
potential risk of acquiring these infections through blood transfusion [3, 10, 21]. Therefore,
this study was conducted to report the prevalence and trends of HBV, HCV and HIV infections
among blood donors in south of Iran during an eleven-year period from 2004 to 2014. This is
the first report on the trends of HBV, HCV and HIV infections among the donor population in
this part of Iran.
Materials and Methods
Study setting and population
This is a retrospective descriptive study of blood donor data recorded at blood transfusion cen-
ters of southern Iran over a period of eleven years. Twelve regional blood transfusion centers
are located in this part of Iran, while Bushehr blood transfusion center as the largest center
contributes in collecting the most of blood units. Bushehr province, which is located in the
northern shores of Persian Gulf, is a commercial port and an important economic center of
southern Iran. The records of all blood donors who donated blood at one of these blood centers
from 2004 to 2014 were analyzed in an anonymous way with respect to the results of serologi-
cal screening for HBV, HCV, and HIV infections. This study was approved by the ethical com-
mittee of Bushehr University of Medical Sciences with reference number IR.BPUMS.
Rec.1394.108.
As a routine pre-donation practice, all of donors went through a physical examination and
health history interview prior to donation in an attempt to ensure their eligibility for donating
blood. Those who had age between 18 and 65 years, body weight above 45 kg, hemoglobin level
of 12.5 g/dL or greater, physical and mental fitness, no history of high-risk behavior, blood
transfusion, jaundice, hepatitis, surgery, and hypertension, as well as the other serious illness
and current fever were considered as eligible donors. Those who were outside the range of eligi-
bility criteria were excluded.
At the time of interviewing, all donors were requested to give a written informed consent to
screen their blood samples for TTIs and use of test results for analysis. All blood donors were
apparently healthy volunteers and classified as first-time donors if they had a history of only
one donation, regular donors if they had a history of more than one donation during one year,
and repeated donors if there was more than one-year intervals between the donations.
Screening methods
After donating blood, all donated blood was screened for the presence of hepatitis B surface
antigen (HBsAg), HIV antigen/antibody (HIV Ag/Ab) and anti hepatitis C virus antibodies
(anti-HCV Ab) using commercially available ELISA kits. All initially positive samples were
retested. The repeatedly reactive samples were labeled seropositive. These seropositive results
were confirmed using HBsAg confirmatory assay, HIV I/II Western Blot (WB), and HCV
recombinant immunoblot assay (RIBA). Regarding HIV, the HIVWB-negative samples were
further evaluated for the presence of HIV P24 antigen, and the reactive samples were con-
firmed using monoclonal neutralization assay. According to the IBTO policies, the initially
positive blood units were excluded, and the confirmed positive donors were recalled for
counseling and appropriate treatment. During the study period, the same kits were used in all
centers (Table 1).
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Table 1. Kits used in donor screening, 2004–2014.
Screening test kits
Year HBsAg screening test kit
(Manufacturer)
Anti-HCV screening test kit(Manufacturer) HIV Ag/Ab screening test kit
(Manufacturer)
2004 ETI-MAK4 HBsAg(DiaSorin, Saluggia,
Italy)
anti-HCV-EIA-Avicenna(Avicenna Medical Centre,
Russia)
Biotest Anti-HIV-1/2 Recombinant(Biotest,
Dreieich, Germany)
2005 ETI-MAK4 HBsAg(DiaSorin, Saluggia,
Italy),Enzygnost HBsAg 5.0(Dade
Behring, Marburg, Germany)
anti-HCV-EIA-Avicenna(Avicenna Medical Centre,
Russia)
Biotest Anti-HIV-1/2 Recombinant(Biotest,
Dreieich, Germany),Genscreen Plus HIV
Ag-Ab(Bio-Rad, California, USA)
2006 Enzygnost HBsAg 5.0(Dade Behring,
Marburg, Germany)
anti-HCV-EIA-Avicenna(Avicenna Medical Centre,
Russia),HCV 3.0 with enhanced SAVe(Ortho-
ClinicalDiagnostics, Inc., Raritan, USA),Hepanostica
Anti-HCV Ultra(BioMerieux, Marcy l'Etoile,France)
Genscreen Plus HIV Ag-Ab(Bio-Rad,
California, USA),Vironostika HIV Uni-Form II
Ag/Ab(BioMerieux, Marcy l'Etoile, France)
2007 Enzygnost HBsAg 5.0(Dade Behring,
Marburg, Germany)
HCV 3.0 with enhanced SAVe(Ortho-
ClinicalDiagnostics, Inc., Raritan, USA),Hepanostica
Anti-HCV Ultra(BioMerieux, Marcy l'Etoile,France)
Genscreen Plus HIV Ag-Ab(Bio-Rad,
California, USA),Vironostika HIV Uni-Form II
Ag/Ab(BioMerieux, Marcy l'Etoile, France)
2008 Enzygnost HBsAg 5.0(Dade Behring,
Marburg, Germany)
HCV 3.0 with enhanced SAVe(Ortho-
ClinicalDiagnostics, Inc., Raritan, USA),Hepanostica
Anti-HCV Ultra(BioMerieux, Marcy l'Etoile, France)
Genscreen Plus HIV Ag-Ab (Bio-Rad,
California, USA),Vironostika HIV Uni-Form II
Ag/Ab(BioMerieux, Marcy l'Etoile, France)
2009 Enzygnost HBsAg 5.0(Dade Behring,
Marburg, Germany)
HCV 3.0 with enhanced SAVe(Ortho-
ClinicalDiagnostics, Inc., Raritan, USA)
Genscreen Plus HIV Ag-Ab (Bio-Rad,
California, USA), Vironostika HIV Uni-Form
II Ag/Ab (BioMerieux, Marcy l'Etoile, France)
2010 Enzygnost HBsAg 5.0(Dade Behring,
Marburg, Germany),Enzygnost HBsAg
6.0(Siemens, Marburg, Germany)
HCV 3.0 with enhanced SAVe(Ortho-
ClinicalDiagnostics, Inc., Raritan, USA),Hepanostica
Anti-HCV Ultra(BioMerieux, Marcy l'Etoile, France)
Genscreen Plus HIV Ag-Ab(Bio-Rad,
California, USA),Vironostika HIV Uni-Form II
Ag/Ab(BioMerieux, Marcy l'Etoile, France)
2011 Enzygnost HBsAg 6.0(Siemens, Marburg,
Germany)
HCV 3.0 with enhanced SAVe(Ortho-
ClinicalDiagnostics, Inc., Raritan, USA), Hepanostica
Anti-HCV Ultra(BioMerieux, Marcy l'Etoile, France)
EIAgen Detect HIV 4 Total Screening Kit
(Adaltis Inc., Montreal, Canada)
2012 Enzygnost HBsAg 6.0(Siemens, Marburg,
Germany)
EIAgen HCV Ab test(Adaltis Inc., Montreal, Canada) EIAgen Detect HIV 4 Total Screening Kit
(Adaltis Inc., Montreal, Canada)
2013 Enzygnost HBsAg 6.0(Siemens, Marburg,
Germany)
EIAgen HCV Ab test(Adaltis Inc., Montreal, Canada) EIAgen Detect HIV 4 Total Screening Kit
(Adaltis Inc., Montreal, Canada)
2014 Enzygnost HBsAg 6.0(Siemens, Marburg,
Germany)
EIAgen HCV Ab test(Adaltis Inc., Montreal, Canada) EIAgen Detect HIV 4 Total Screening Kit
(Adaltis Inc., Montreal, Canada)
Conﬁrmatory test kits
Year HBsAg conﬁrmatory test
(Manufacturer)
HCV RIBA(Manufacturer) HIV Western Blot(Manufacturer)
2004 HBsAg conﬁrmatory test(DiaSorin,
Saluggia, Italy)
HCV Blot 3.0(Genelabs diagnostics, Singapore) HIV Blot 2.2(Genelabs diagnostics,
Singapore)
2005 HBsAg conﬁrmatory test(DiaSorin,
Saluggia, Italy), HBsAg conﬁrmatory test
(Dade Behring, Marburg, Germany)
HCV Blot 3.0(Genelabs diagnostics, Singapore) HIV Blot 2.2(Genelabs diagnostics,
Singapore)
2006 HBsAg conﬁrmatory test(Dade Behring,
Marburg, Germany)
HCV Blot 3.0(Genelabs diagnostics, Singapore) HIV Blot 2.2(Genelabs diagnostics,
Singapore)
2007 HBsAg conﬁrmatory test(Dade Behring,
Marburg, Germany)
MP Diagnostics HCV BLOT 3.0(MP Biomedicals,
California, USA)
HIV Blot 2.2(Genelabs diagnostics,
Singapore),MP Diagnostics HIV Blot 2.2(MP
Biomedicals, California, USA)
2008 HBsAg conﬁrmatory test(Dade Behring,
Marburg, Germany)
MP Diagnostics HCV BLOT 3.0(MP Biomedicals,
California, USA)
HIV Blot 2.2(Genelabs diagnostics,
Singapore),MP Diagnostics HIV Blot 2.2(MP
Biomedicals, California, USA)
2009 HBsAg conﬁrmatory test(Dade Behring,
Marburg, Germany), HBsAg conﬁrmatory
test(Siemens, Marburg, Germany)
HCV Blot 3.0(Genelabs diagnostics, Singapore) HIV Blot 2.2(Genelabs diagnostics,
Singapore),MP Diagnostics HIV Blot 2.2
(MP Biomedicals, California, USA)
2010 HBsAg conﬁrmatory test(Siemens,
Marburg, Germany)
MP Diagnostics HCV BLOT 3.0(MP Biomedicals,
California, USA)
MP Diagnostics HIV Blot 2.2(MP
Biomedicals, California, USA)
2011 HBsAg conﬁrmatory test(Siemens,
Marburg, Germany)
HCV Blot 3.0(Genelabs diagnostics, Singapore) MP Diagnostics HIV Blot 2.2(MP
Biomedicals, California, USA)
(Continued)
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Statistical analysis
Data were entered in Microsoft Excel sheets and analyzed using OpenEpi statistical software
(Available at http://openepi.com/Menu/OE_Menu.htm). All data were provided as frequencies
and percentages for basic descriptive purposes. The yearly seroprevalence rates of TTIs were
presented for the entire study population and different socio-demographic categories. Chi-
square test was used to compare the seroprevalence rates of TTIs among blood donors grouped
according to socio-demographic characteristics and evaluate the impact of categorical variables
on TTIs seropositivity. Chi-square test for trend was used to analyze the variations in trends of
TTIs during this eleven-year period. Statistically, P values of less than 0.05 were accepted as
significant.
Results
During the 11-year period from 2004 through 2014, 376568 individuals volunteered to donate
blood. Of them, 293454 (77.93%) donors were screened for viral infections, and 83114
(22.07%) candidates were deferred by the pre-donation questionnaire. A gradual increase in
the number of donors was observed over time from 1337.4 donors per 100,000 population in
2004 to 3310.8 donors per 100,000 population in 2014. Out of 293454 donors, 274556 (93.5%)
were males and 18898 (6.5%) were females, 239211 (81.5%) were married while 54243 (18.5%)
were single. Regular donors represented the majority of donors, followed by first time donors
and repeated donors. A considerable percentage of the donors were educated and a few illiter-
ate, 62.5% had diploma or higher level of education. The age groups 20–30 years and 31–40
years contributed a large percentage of all donations. The majority of blood donations (84.5%)
were obtained from Bushehr and Borazjan cities, while the remaining donations (15.5%) were
collected from the other cities. Private business owners, clerical workers and military personnel
constituted the majority of donors. The socio-demographic characteristics of donors, including
gender, marital status, type of donor, education level, age, place of residency and profession are
summarized in Table 2.
Of 293454 donors, 747 were determined to be seropositive for any of the screened TTIs,
revealing an overall seroprevalence rate of 0.254% for TTIs. Overall, the seroprevalence rates of
HBV, HCV and HIV were 0.15% (440), 0.1% (295) and 0.004% (12), respectively. None of the
blood donors had co-infection with these viruses.
The seroprevalence of HCV, HIV and HBV infections in male donors was 0.104%, 0.004%
and 0.150%, respectively, and the corresponding figures for females were 0.047%, 0% and
0.137%, respectively. Although HBV and HCV infections were more prevalent among male
donors compared to the females, but only difference in the prevalence of HCV was statistically
significant (P = 0.017). Regarding HIV infection, no seropositive case was found among the
female donors.
The seroprevalence of HCV and HIV were higher among single donors, whereas HBV
infection was more prevalent among married donors. The seroprevalence of HCV, HIV and
Table 1. (Continued)
2012 HBsAg conﬁrmatory test(Siemens,
Marburg, Germany)
MP Diagnostics HCV BLOT 3.0(MP Biomedicals,
California, USA)
MP Diagnostics HIV Blot 2.2(MP
Biomedicals, California, USA)
2013 HBsAg conﬁrmatory test(Siemens,
Marburg, Germany)
MP Diagnostics HCV BLOT 3.0(MP Biomedicals,
California, USA)
MP Diagnostics HIV Blot 2.2(MP
Biomedicals, California, USA)
2014 HBsAg conﬁrmatory test(Siemens,
Marburg, Germany)
MP Diagnostics HCV BLOT 3.0(MP Biomedicals,
California, USA)
MP Diagnostics HIV Blot 2.2(MP
Biomedicals, California, USA)
doi:10.1371/journal.pone.0157615.t001
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Table 2. Socio-demographic characteristics of blood donors in south of Iran, 2004–2014.
2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 Total
Number of
donors
11,521 17,735 19,073 25,573 28,065 26,509 28,936 32,952 33,524 34,586 34,980 293,454
GenderN(%)
Male 10,366
(90.0)
16,097
(90.8)
17,549
(92.0)
23,613
(92.3)
26,325
(93.8)
24,903
(94.0)
27,126
(93.8)
30,936
(93.9)
31,593
(94.2)
32,841
(95.0)
33,207
(95.0)
274,556
(93.5)
Female 1,155
(10.0)
1,638
(9.2)
1,524
(8.0)
1,960
(7.7)
1,740
(6.2)
1,606
(6.0)
1,810
(6.2)
2,016
(6.1)
1,931
(5.8)
1,745
(5.0)
1,773
(5.0)
18,898
(6.5)
Marital statusN
(%)
Single 2,634
(22.9)
3,679
(20.7)
3,628
(19.0)
5,181
(20.3)
5,288
(18.8)
4,723
(17.8)
5,475
(19.0)
5,691
(17.3)
5,937
(17.7)
6,074
(17.5)
5,933
(17.0)
54,243
(18.5)
Married 8,887
(77.1)
14,056
(79.3)
15,445
(81.0)
20,392
(79.7)
22,777
(81.2)
21,786
(82.2)
23,461
(81.0)
27,261
(82.7)
27,587
(82.3)
28,512
(82.5)
29,047
(83.0)
239,211
(81.5)
Type of blood
donor N(%)
First-time donor 9,799
(85.05)
10,409
(58.7)
8421
(44.1)
11,959
(46.8)
10,351
(36.9)
8,392
(31.7)
8,666
(30.0)
8,473
(25.7)
7,895
(23.6)
7,700
(22.3)
6,708
(19.2)
98,773
(33.6)
Repeated donor 6(0.05) 626(3.5) 2,645
(13.9)
3,995
(15.6)
4,944
(17.6)
5,896
(22.2)
6,199
(21.4)
6,795
(20.6)
7,583
(22.6)
7,974
(23.0)
8,450
(24.2)
55,113
(18.8)
Regular donor 1,716
(14.9)
6,700
(37.8)
8,007
(42.0)
9,619
(37.6)
12,770
(45.5)
12,221
(46.1)
14,071
(48.6)
17,684
(53.7)
18,046
(53.8)
18,912
(54.7)
19,822
(56.6)
139,568
(47.6)
Level of
educationN(%)
Illiterate 411(3.6) 601(3.4) 589
(3.08)
923(3.6) 894(3.2) 841(3.2) 815(2.8) 908(2.7) 822(2.5) 749(2.2) 754(2.1) 8,307
(2.8)
Under diploma 3,918
(34.0)
6,198
(34.9)
6,979
(36.6)
9,465
(37.0)
9,912
(35.3)
9,327
(35.2)
9,995
(34.6)
11,362
(34.5)
11,001
(32.8)
11,568
(33.4)
11,592
(33.1)
101,317
(34.6)
Diploma 5,015
(43.5)
7,573
(42.7)
7,761
(40.7)
10,232
(40.0)
11,405
(40.7)
10,983
(41.4)
11,880
(41.0)
13,041
(39.6)
13,455
(40.1)
13,412
(38.8)
13,557
(38.8)
118,314
(40.3)
Higher diploma 2,177
(18.9)
3,363
(19.0)
3,738
(19.6)
4,918
(19.3)
5,704
(20.3)
5,270
(19.9)
6,193
(21.4)
7,640
(23.2)
8,246
(24.6)
8,857
(25.6)
9,077
(26.0)
65,183
(22.2)
No record 0(0.0) 0(0.0) 6(0.03) 35(0.14) 150
(0.53)
88(0.33) 53(0.2) 1(0.003) 0(0.0) 0(0.0) 0(0.0) 333(0.11)
Age groups
(years) N(%)
<20 1,180
(10.2)
2,241
(12.6)
3,698
(19.4)
2,444
(9.6)
1,767
(6.3)
1,384
(5.2)
1,326
(4.6)
1,198
(3.6)
1,017
(3.0)
837(2.4) 703(2.0) 17,795
(6.0)
20–30 4,313
(37.4)
6,409
(36.1)
6,331
(33.2)
9,297
(36.3)
10,658
(38.0)
9,677
(36.5)
10,320
(35.6)
11,584
(35.2)
11,411
(34.0)
11,185
(32.3)
10,362
(29.6)
101,547
(34.6)
31–40 3,340
(29.0)
5,008
(28.2)
4,979
(26.1)
7,499
(29.3)
8,734
(31.1)
8,530
(32.2)
9,367
(32.4)
10,813
(32.8)
11,304
(33.8)
12,198
(35.3)
12,902
(36.9)
94,674
(32.3)
41–50 1,968
(17.1)
2,952
(16.7)
2,938
(15.4)
4,495
(17.6)
4,978
(17.7)
4,903
(18.5)
5,555
(19.2)
6,527
(19.8)
6,839
(20.4)
7,326
(21.2)
7,871
(22.5)
56,352
(19.2)
51–60 667(5.8) 1,008
(5.7)
1,035
(5.4)
1,708
(6.7)
1,786
(6.4)
1,895
(7.2)
2,221
(7.7)
2,665
(8.1)
2,739
(8.2)
2,853
(8.3)
3,007
(8.6)
21,584
(7.4)
>60 53(0.5) 117(0.7) 92(0.5) 130(0.5) 142(0.5) 120(0.4) 147(0.5) 165(0.5) 214(0.6) 187(0.5) 135(0.4) 1,502
(0.5)
Place of
residenceN(%)
Bushehr 10,275
(89.2)
13,472
(76.0)
18,736
(98.2)
17,816
(69.7)
15,788
(56.3)
15,248
(57.5)
16,753
(57.9)
19,347
(58.7)
20,001
(59.7)
19,899
(57.5)
20,768
(59.4)
188,103
(64.1)
Genaveh 617(5.4) 1,630
(9.2)
133(0.7) 298(1.2) 1,237
(4.4)
2,177
(8.2)
2,121
(7.3)
2,306
(7.0)
2,574
(7.7)
2,406
(7.0)
2,572
(7.3)
18,071
(6.2)
(Continued)
Viral Infections in Blood Donors
PLOS ONE | DOI:10.1371/journal.pone.0157615 June 16, 2016 6 / 18
HBV infections among single donors was 0.132%, 0.007% and 0.114%, respectively. While the
corresponding figures among married donors were 0.093%, 0.003% and 0.158%, respectively.
No significant difference in HIV prevalence was observed between the donors regarding mari-
tal status, while the differences in the prevalence of HBV and HCV were statistically significant
(P = 0.017 and P = 0.008, respectively). Compared to regular and repeated donors, first-time
donors were significantly more infected by HBV (P< 0.001), HCV (P< 0.001) and HIV
(P = 0.001), while the frequency of these three pathogens was the lowest in regular donors.
The seroprevalence of TTIs decreased with education level, so that highly educated donors
showed lower seropositivity rates. Overall, there were significant differences in HBV and HCV
seroprevalence rates between the donors grouped according to level of education (P< 0.001,
Table 2. (Continued)
2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 Total
Borazjan 59(0.5) 1(0.006) 0(0.0) 5,623
(22.0)
7,254
(25.9)
6,200
(23.4)
7,329
(25.3)
8,189
(24.9)
8,089
(24.1)
8,642
(25.0)
8,629
(24.7)
60,015
(20.4)
Khormuj 162(1.4) 401(2.3) 72(0.4) 339(1.3) 756(2.7) 556(2.1) 474(1.6) 276
(0.84)
397(1.2) 245
(0.70)
299
(0.85)
3,977
(1.3)
Khark 101(0.9) 532(3.0) 38(0.2) 290(1.1) 860(3.0) 499(1.9) 190
(0.66)
322
(0.98)
247
(0.74)
279
(0.80)
340
(0.97)
3,698
(1.3)
Ahram 65(0.6) 350(2.0) 31(0.16) 370(1.4) 420(1.5) 364(1.4) 204
(0.70)
98(0.30) 269
(0.80)
81(0.23) 121
(0.34)
2,373
(0.80)
Jam 155(1.3) 650(3.6) 50(0.3) 459(1.8) 760(2.7) 559(2.1) 499(1.7) 320
(0.97)
433(1.3) 339
(0.98)
371
(1.06)
4,595
(1.6)
Dayer 38(0.3) 127(0.7) 3(0.02) 76(0.3) 210
(0.74)
227
(0.85)
108(0.4) 147
(0.45)
89(0.26) 79(0.23) 65(0.19) 1,169
(0.4)
Kangan 0(0.0) 359
(2.02)
0(0.0) 198(0.8) 488
(1.73)
459
(1.73)
1,034
(3.6)
1821
(5.5)
1216
(3.6)
2526
(7.3)
1610
(4.6)
9,711
(3.3)
Deylam 34(0.3) 143(0.8) 0(0.0) 103(0.4) 240
(0.85)
147
(0.55)
101
(0.35)
87(0.26) 136
(0.40)
61(0.18) 76(0.22) 1,128
(0.4)
Tange eram 10(0.09) 40(0.22) 3(0.02) 0(0.0) 34(0.12) 45(0.17) 86(0.30) 23(0.07) 44(0.13) 25(0.07) 87(0.25) 397(0.13)
Abpakhsh 5(0.04) 30(0.17) 7(0.04) 1(0.004) 18(0.06) 28(0.10) 37(0.13) 16(0.05) 29(0.09) 4(0.01) 42(0.12) 217(0.07)
OccupationN(%)
Private business
owner
4,209
(36.6)
7,325
(41.3)
8,398
(44.0)
11,497
(45.0)
13,117
(46.8)
12,692
(47.9)
14,097
(48.7)
15,920
(48.3)
16,238
(48.4)
17,470
(50.5)
17,856
(51.0)
138,819
(47.3)
Clerical worker 3,466
(30.1)
4,953
(27.9)
5,190
(27.2)
6,960
(27.2)
7,198
(25.7)
6,590
(24.9)
6,938
(24.0)
7,703
(23.4)
7,935
(23.7)
7,864
(22.7)
7,872
(22.5)
72,669
(24.8)
Homemaker 1,028
(8.9)
1,506
(8.5)
1,488
(7.8)
1,813
(7.1)
1,640
(5.8)
1,468
(5.5)
1,543
(5.3)
1,812
(5.5)
1,648
(4.9)
1,515
(4.4)
1,562
(4.5)
17,023
(5.8)
Military personnel 1,676
(14.6)
2,268
(12.8)
2,076
(10.9)
2,917
(11.4)
3,319
(11.8)
3,052
(11.5)
3,310
(11.4)
3,774
(11.5)
3,736
(11.14)
3,621
(10.5)
3,726
(10.7)
33,475
(11.4)
Retiree 124
(1.08)
221(1.2) 250(1.3) 335(1.3) 303
(1.08)
342(1.3) 436(1.5) 619(1.9) 618
(1.84)
587(1.7) 603(1.7) 4,438
(1.5)
Pupil 124
(1.08)
182
(1.03)
208(1.1) 316(1.2) 310(1.1) 388(1.5) 419(1.5) 357
(1.08)
344
(1.03)
318
(0.92)
299
(0.85)
3,265
(1.1)
University student 497(4.3) 762(4.3) 844(4.4) 927(3.6) 1,189
(4.2)
1,121
(4.2)
1,299
(4.5)
1,369
(4.15)
1,412
(4.2)
1,473
(4.2)
1,344
(3.8)
12,237
(4.16)
Conscript 212(1.8) 245(1.4) 354(1.9) 385(1.5) 512(1.8) 372(1.4) 326
(1.12)
291
(0.88)
245
(0.73)
266
(0.77)
301
(0.86)
3,509
(1.2)
Unemployed 153(1.3) 244(1.4) 238(1.2) 359(1.4) 445(1.6) 435(1.6) 513(1.8) 805(2.4) 956(2.9) 996(2.9) 902(2.6) 6,046
(2.06)
Others 32(0.28) 29(0.16) 27(0.14) 64(0.25) 32(0.11) 49(0.18) 55(0.19) 302
(0.91)
392
(1.17)
476(1.4) 515(1.5) 1,973
(0.67)
doi:10.1371/journal.pone.0157615.t002
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P< 0.001, respectively). For HIV, a small but not significant difference was observed between
donors with diploma and under diploma education levels (P = 0.173).
There were significant differences in the seroprevalence of HBV and HCV between the age
groups (P = 0.014 and P = 0.005, respectively). HBV seroprevalence increased with age, from
0.089% in donors under 20 years old to 0.399% in donors over 60 years old. As for HCV, the
highest rate of HCV seroprevalence was observed in the age group 31–40 years followed by age
group 20–30 years. While donors in the age group 51–60 years showed the lowest positivity
rate.
HIV seropositivity was only observed in the age groups 20–30 and 31–40 years. However,
HIV was more prevalent in donors aged 20–30 years, but this difference was not significant
(P = 0.183).
HBV seropositivity was observed among donor populations of all the cities, while no posi-
tive HCV case was found in blood donors from Abpakhsh city. In addition, HIV seropreva-
lence was only observed in Bushehr, Genaveh and Borazjan cities, and no significant difference
was reported among these cities (P = 0.997). Meanwhile, significant differences in the seroprev-
alence of HBV (P = 0.004) and HCV (P< 0.001) were observed between the donors regarding
the place of residency. The highest seroprevalence rates of HBV and HCV were observed
among donors in Abpakhsh and Tange Eram cities, respectively. While Genaveh and Jam cities
had the lowest rates of hepatitis B and C among blood donors in this region, respectively.
There were statistical differences in the prevalence rates of HBV (P = 0.021) and HCV
(P< 0.001) between the donors grouped according to their occupation. Conscripts (0.227%)
and retirees (0.225%) had the highest seroprevalence rates for HBV, while unemployed
(0.215%) displayed the highest seroprevalence for HCV. On the other hand, university students
(0.049%) and retirees (0.022%) showed the lowest seroprevalence rates for HBV and HCV
infections, respectively. However, HIV seroprevalence was higher among private business own-
ers, it was not statistically associated with working status (P = 0.379). The yearly distribution of
HBV, HCV and HIV seropositivity among donors grouped according to socio-demographic
characteristics is shown in Tables 3–5, respectively.
Overall, TTIs were more prevalent in male, low educated and first-time donors during the
study period. Over this 11-year period, seroprevalence rates of HBV and HCV showed signifi-
cant decreasing trends from 0.460% to 0.060% (P< 0.001) and 0.329% to 0.045% (P< 0.001),
respectively. Whereas prevalence of HIV infection had a slight but not significant decline from
0.0173% in 2004 to 0.0028% in 2014 (P = 0.087). The trends of HBV, HCV and HIV infections
in all blood donations from 2004 to 2014 are shown in Fig 1. Overall, the most prevalent TTIs
were HBV followed by HCV, while the prevalence of HIV infection was the lowest in southern
Iran.
Discussion
Blood transfusion is considered as a potential risk factor for transmission of life-threatening
viruses, including mainly HBV, HCV and HIV [1, 5]. Therefore, efficient strategies should be
implemented to reduce this risk to the minimum. Prevention of these infections is achievable
by continuous screening of all blood donations for these viruses [1, 10, 17, 22]. According to
the epidemiological reports, the risk of transmission of viral infections has been noticeably
decreased in countries where continuous screening of all blood donations for TTIs is carried
out [8, 17, 21]. In Iran, the serological screening of all donated blood is mandatory for HBV,
HCV and HIV [8, 17, 19, 20]. In recent years, Iranian Blood Transfusion Organization (IBTO)
has implemented more restrictive donor selection criteria through application of strict and
standard questionnaire, confidential unit exclusion, and effective procedures in physical
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Table 3. Yearly seroprevalence of HBV infection among blood donors according to socio-demographic characteristics.
2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 Total P
value
HBV positive 53
(0.460)
70
(0.394)
48
(0.251)
53
(0.207)
44
(0.156)
46
(0.173)
30
(0.103)
28
(0.084)
25
(0.074)
22
(0.063)
21
(0.060)
440
(0.149)
<0.001
GenderN(%) 0.649
Male 51
(0.491)
66
(0.410)
46
(0.262)
50
(0.211)
40
(0.151)
44
(0.176)
29
(0.106)
27
(0.087)
23
(0.072)
20
(0.060)
18
(0.054)
414
(0.150)
Female 2
(0.173)
4
(0.244)
2
(0.131)
3
(0.153)
4
(0.229)
2
(0.124)
1
(0.055)
1
(0.049)
2
(0.103)
2
(0.114)
3
(0.169)
26
(0.137)
Marital statusN
(%)
0.017
Single 7
(0.265)
5
(0.135)
6
(0.165)
10
(0.193)
7
(0.132)
7
(0.148)
6
(0.109)
2
(0.035)
5
(0.084)
4
(0.065)
3
(0.050)
62
(0.114)
Married 46
(0.517)
65
(0.462)
42
(0.271)
43
(0.210)
37
(0.162)
39
(0.179)
24
(0.102)
26
(0.095)
20
(0.072)
18
(0.063)
18
(0.061)
378
(0.158)
Type of blood
donorsN(%)
<0.001
First-time donor 50
(0.510)
63
(0.605)
39
(0.463)
51
(0.426)
42
(0.405)
43
(0.512)
30
(0.346)
25
(0.295)
23
(0.291)
20
(0.259)
19
(0.283)
405
(0.410)
Repeated donor 1
(0.159)
5
(0.189)
1
(0.025)
3
(0.050)
1
(0.014)
1
(0.013)
2
(0.023)
14
(0.025)
Regular donor 3
(0.174)
6
(0.089)
4
(0.049)
1
(0.010)
2
(0.015)
2
(0.011)
1
(0.005)
2
(0.010)
21
(0.015)
Level of
educationN(%)
<0.001
Illiterate 1
(0.243)
4
(0.665)
4
(0.679)
4
(0.433)
3
(0.335)
1
(0.118)
2
(0.245)
6
(0.660)
3
(0.397)
28
(0.337)
Under diploma 13
(0.331)
23
(0.371)
27
(0.386)
28
(0.295)
26
(0.262)
25
(0.268)
14
(0.140)
10
(0.088)
15
(0.136)
10
(0.086)
11
(0.094)
202
(0.199)
Diploma 27
(0.538)
33
(0.435)
13
(0.167)
19
(0.185)
8
(0.070)
15
(0.136)
9
(0.075)
9
(0.069)
6
(0.044)
5
(0.037)
3
(0.022)
147
(0.124)
Higher diploma 12
(0.551)
10
(0.297)
4
(0.107)
2
(0.040)
7
(0.122)
5
(0.094)
5
(0.080)
3
(0.039)
4
(0.048)
7
(0.079)
4
(0.044)
63
(0.096)
Age groups
(years)N(%)
0.014
<20 5
(0.423)
3
(0.133)
1
(0.027)
4
(0.163)
2
(0.144)
1
(0.142)
16
(0.089)
20–30 18
(0.417)
23
(0.358)
22
(0.347)
17
(0.182)
16
(0.150)
16
(0.165)
15
(0.145)
8
(0.069)
8
(0.070)
6
(0.053)
3
(0.028)
152
(0.149)
31–40 16
(0.479)
25
(0.499)
17
(0.341)
12
(0.160)
12
(0.137)
15
(0.175)
8
(0.085)
8
(0.073)
7
(0.061)
5
(0.040)
6
(0.046)
131
(0.138)
41–50 11
(0.558)
16
(0.542)
6
(0.204)
10
(0.222)
8
(0.160)
12
(0.244)
5
(0.090)
6
(0.091)
8
(0.116)
8
(0.109)
8
(0.101)
98
(0.173)
51–60 3
(0.449)
3
(0.297)
2
(0.193)
9
(0.526)
4
(0.223)
1
(0.052)
1
(0.045)
6
(0.225)
2
(0.073)
3
(0.105)
3
(0.099)
37
(0.171)
>60 1
(0.854)
1
(1.086)
1
(0.769)
2
(1.408)
1
(0.680)
6
(0.399)
Place of
residenceN(%)
0.004
Bushehr 49
(0.476)
64
(0.475)
48
(0.256)
43
(0.241)
26
(0.164)
25
(0.163)
14
(0.083)
15
(0.077)
15
(0.074)
11
(0.055)
7
(0.033)
317
(0.168)
Borazjan 10
(0.177)
9
(0.124)
10
(0.161)
5
(0.068)
6
(0.073)
9
(0.111)
7
(0.081)
9
(0.104)
65
(0.108)
(Continued)
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examination prior to donation as well as educational program regarding blood donation to
improve the blood safety [8, 9, 17, 19, 20]. As a result, elimination or reduction of the risk of
transmitting viral infection through blood transfusion has been predicted. In addition, public
awareness regarding the general prevalence and transmission routes of viral infections has a
considerable effect on the rates of these infections in donor population [8, 9, 17, 19, 20]. Moni-
toring the prevalence trends of viral infections in the donor population is a valuable index for
evaluating the effectiveness of strategies implemented by IBTO [8, 17, 19, 20]. Therefore, the
current study was conducted with the objective to find out the prevalence and trends of HBV,
HCV and HIV infections in all blood donations from 2004 to 2014.
Table 3. (Continued)
2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 Total P
value
Kangan 1
(0.204)
1
(0.217)
6
(0.580)
5
(0.274)
3
(0.118)
5
(0.310)
21
(0.216)
Genaveh 1
(0.162)
6
(0.368)
2
(0.161)
1
(0.045)
1
(0.047)
1
(0.038)
12
(0.066)
Khormuj 3
(1.851)
1
(0.132)
1
(0.179)
2
(0.421)
7
(0.176)
Jam 1
(0.131)
2
(0.357)
2
(0.400)
1
(0.294)
6
(0.130)
Ahram 1
(0.238)
2
(0.549)
3
(0.126)
Dayer 1
(0.440)
2
(1.360)
3
(0.256)
Khark 2
(0.232)
1
(0.200)
3
(0.081)
Deylam 1
(0.416)
1
(0.088)
Tange eram 1
(2.222)
1
(0.251)
Abpakhsh 1
(3.571)
1
(0.460)
OccupationN(%) 0.021
Private business
owner
14
(0.332)
34
(0.464)
29
(0.345)
37
(0.321)
24
(0.182)
28
(0.220)
21
(0.148)
15
(0.094)
14
(0.086)
7
(0.040)
8
(0.044)
231
(0.166)
Clerical worker 19
(0.548)
18
(0.363)
11
(0.211)
7
(0.100)
9
(0.125)
8
(0.121)
7
(0.100)
6
(0.077)
4
(0.050)
10
(0.127)
7
(0.088)
106
(0.145)
University student 1
(0.201)
2
(0.262)
1
(0.107)
2
(0.168)
6
(0.049)
Homemaker 2
(0.194)
4
(0.265)
2
(0.134)
3
(0.165)
3
(0.182)
2
(0.136)
1
(0.064)
1
(0.055)
2
(0.121)
2
(0.132)
3
(0.192)
25
(0.146)
Military personnel 11
(0.656)
10
(0.440)
3
(0.144)
3
(0.102)
3
(0.090)
4
(0.131)
4
(0.105)
3
(0.080)
41
(0.122)
Unemployed 2
(1.307)
1
(0.409)
1
(0.278)
2
(0.248)
1
(0.104)
2
(0.200)
1
(0.110)
10
(0.165)
Retiree 2
(1.612)
1(0.4) 1
(0.298)
2
(0.660)
1
(0.292)
1
(0.229)
1
(0.161)
1
(0.165)
10
(0.225)
Pupil 1
(0.549)
1
(0.316)
1
(0.257)
3
(0.091)
Conscript 2
(0.943)
2
(0.564)
2
(0.537)
1
(0.375)
1
(0.332)
8
(0.227)
doi:10.1371/journal.pone.0157615.t003
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Table 4. Yearly seroprevalence of HCV infection among blood donors according to socio-demographic characteristics.
2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 Total P
value
HCV positive 38
(0.329)
42
(0.236)
41
(0.214)
43
(0.168)
25
(0.089)
28
(0.105)
18
(0.062)
10
(0.030)
18
(0.053)
16
(0.046)
16
(0.045)
295
(0.100)
<0.001
GenderN(%) 0.017
Male 37
(0.356)
42
(0.260)
40
(0.227)
42
(0.177)
24
(0.091)
27
(0.108)
18
(0.066)
10
(0.032)
16
(0.050)
14
(0.042)
16
(0.048)
286
(0.104)
Female 1(0.086) 1(0.065) 1(0.051) 1(0.057) 1(0.062) 2(0.103) 2(0.114) 9(0.047)
Marital statusN(%) 0.008
Single 13
(0.493)
12
(0.326)
10
(0.275)
12
(0.231)
4(0.075) 6(0.127) 2(0.036) 2(0.035) 4(0.067) 3(0.049) 4(0.067) 72
(0.132)
Married 25
(0.281)
30
(0.213)
31
(0.200)
31
(0.152)
21
(0.092)
22
(0.100)
16
(0.068)
8(0.029) 14
(0.050)
13
(0.045)
12
(0.041)
223
(0.093)
Type of blood
donorsN(%)
<0.001
First-time donor 38
(0.387)
36
(0.345)
37
(0.439)
37
(0.309)
22
(0.212)
28
(0.333)
17
(0.196)
10
(0.118)
13
(0.164)
15
(0.194)
12
(0.178)
265
(0.268)
Repeated donor 4(0.151) 5(0.125) 2(0.040) 4(0.052) 1(0.012) 2(0.023) 18
(0.032)
Regular donor 6(0.089) 1(0.010) 1(0.007) 1(0.007) 1(0.005) 2(0.010) 12
(0.008)
Level of educationN
(%)
<0.001
Illiterate 3(0.729) 1(0.169) 1(0.122) 1(0.133) 6(0.072)
Under diploma 23
(0.587)
28
(0.451)
21
(0.300)
30
(0.316)
14
(0.141)
18
(0.192)
14
(0.140)
5(0.044) 10
(0.090)
8(0.069) 7(0.060) 178
(0.175)
Diploma 10
(0.199)
9(0.118) 15
(0.193)
10
(0.097)
8(0.070) 8(0.072) 4(0.030) 6(0.044) 5(0.037) 7(0.051) 82
(0.069)
Higher diploma 2(0.091) 5(0.148) 4(0.107) 3(0.061) 3(0.052) 2(0.037) 3(0.048) 1(0.013) 2(0.024) 2(0.022) 2
(0.022)
29
(0.044)
Age groups(years)N
(%)
0.005
<20 2(0.169) 2(0.089) 2(0.054) 1(0.040) 2(0.113) 1(0.142) 10
(0.056)
20–30 19
(0.440)
21
(0.327)
18
(0.284)
16
(0.172)
10
(0.093)
8(0.082) 2(0.019) 2(0.017) 3(0.026) 5(0.048) 104
(0.102)
31–40 8(0.239) 14
(0.279)
18
(0.361)
18
(0.240)
9(0.103) 15
(0.175)
10
(0.106)
3(0.027) 11
(0.097)
8(0.065) 7(0.054) 121
(0.127)
41–50 4(0.203) 5(0.169) 2(0.068) 7(0.155) 4(0.080) 5(0.101) 6(0.108) 4(0.061) 4(0.058) 3(0.040) 3(0.038) 47
(0.083)
51–60 4(0.599) 1(0.096) 1(0.058) 1(0.037) 3(0.109) 2(0.070) 12
(0.055)
>60 1(1.886) 1(0.066)
Place of residenceN
(%)
<0.001
Bushehr city 34
(0.330)
39
(0.289)
41
(0.218)
43
(0.241)
15
(0.095)
12
(0.078)
11
(0.065)
4(0.020) 12
(0.059)
12
(0.060)
13
(0.062)
236
(0.125)
Borazjan 6(0.082) 8(0.129) 1(0.013) 1(0.012) 3(0.037) 2(0.023) 3(0.034) 24
(0.039)
Genaveh 3(0.486) 3(0.184) 2(0.161) 5(0.229) 2(0.094) 1(0.043) 2(0.077) 2(0.083) 20
(0.110)
Khark 1(0.116) 2(0.621) 3(0.081)
Ahram 1(0.274) 1(0.490) 1(0.371) 3(0.126)
Kangan 1(0.096) 2(0.109) 3(0.030)
Khormuj 1(0.617) 1(0.132) 2(0.050)
Jam 1(0.178) 1(0.021)
Dayer 1(0.440) 1(0.085)
Deylam 1(0.990) 1(0.088)
(Continued)
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The results of this study demonstrate very low rates of viral infections in blood donations in
Southern Iran. The seroprevalence rate of 0.15% for HBV observed in the present study is
lower than those reported in previous studies from Iran, 3.4% in 1979 [23], 1.79% in 1998 [20],
0.6% in 2003–2005 [18], 0.56% in 2004–2007 [8], 0.41% in 2007 [20], 0.23% in 2009 [24], and
0.38% in 2005–2011 [19]. This is probably because of population differences regarding social
behavior, lifestyle, socioeconomic status and level of awareness in different regions of our
country. However, some differences in specificity and sensitivity of screening tests, number of
first-time donors, and geographical distribution of the infection as well as the burden of the dis-
ease in the society can also explain a part of these variations. The reported prevalence in this
study is also lower than those of Mangalore (0.5%) [1], Ethiopia (4.7%) [25], China (0.87%)
[21], Mongolia (8.1%) [26], Pakistan (1.46%-2.99%) [22], Nepal (0.47%) [2], and Nigeria
(11.1%) [6] but higher than those of Canada (0.007%-0.06%) [27], Australia (0.01%) [28], and
Italy (0.0069%) [29]. Generally, the prevalence of HBV infection among blood donors is low in
developed countries, while it is higher in developing countries. These geographical differences
in prevalence of HBV infection might be due to some differences in socioeconomic status,
health behaviors and attitudes, standard of life, risk behaviors, rate of this infection in the gen-
eral population, immunization status, public education, level of safety measures in public
health services, effectiveness of donor selection program, and quality of blood screening tests
in different parts of the world.
Our findings also indicate that older donors are more prevalent infected by HBV than youn-
ger donors. This increasing prevalence with age may be associated with increased exposure to
HBV most likely due to the possibility of engaging more in risky behaviors over time [4, 30].
Risky sexual activities like multiple sex partnerships more efficiently transmit HBV than HCV
and HIV, while HCV transmission by sexual intercourse is less common [31–33]. In contrast,
HCV is efficiently transmitted by injecting drug use, which is more common among youths in
Iran [9]. Furthermore, among blood borne and sexually transmitted viruses, HBV has a low
infectious dose, thus making high risk non-vaccinated population more likely to get infected
[34]. In fact, initiation of HBV vaccination program for all newborns in Iran in 1993 as well as
vaccination of teenagers and high-risk groups since 2006 also had an important role in decreas-
ing the prevalence of HBV infection among youths [16]. This is consistent with previous
Table 4. (Continued)
2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 Total P
value
Tange eram 1(1.162) 1(0.251)
OccupationN(%) <0.001
Private business owner 30
(0.712)
30
(0.409)
30
(0.357)
31
(0.269)
19
(0.144)
23
(0.181)
14
(0.099)
8(0.050) 12
(0.073)
8(0.045) 9(0.050) 214
(0.154)
Clerical worker 5(0.144) 6(0.121) 6(0.115) 5(0.071) 2(0.027) 2(0.030) 3(0.043) 1(0.012) 2(0.025) 3(0.038) 4(0.050) 39
(0.053)
University student 1(0.131) 1(0.118) 1(0.084) 1(0.067) 1(0.074) 5(0.040)
Homemaker 1(0.097) 1(0.067) 1(0.055) 1(0.068) 1(0.060) 2(0.132) 7(0.041)
Military personnel 2(0.119) 2(0.088) 1(0.048) 2(0.068) 1(0.030) 1(0.026) 1(0.026) 10
(0.029)
Unemployed 2(0.819) 2(0.840) 3(0.835) 1(0.224) 1(0.229) 1(0.194) 1(0.124) 2(0.209) 13
(0.215)
Retiree 1(0.170) 1(0.022)
Pupil 1(0.322) 1(0.030)
Conscript 1(0.408) 1(0.259) 1(0.375) 1(0.332) 4(0.113)
Others 1(2.040) 1(0.050)
doi:10.1371/journal.pone.0157615.t004
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studies, which have demonstrated a considerable association between higher HBV seropreva-
lence and older ages [4, 8, 21, 27, 30]. While some other studies have shown higher prevalence
among younger age groups [1, 3, 6, 25, 35]. Differences in risk factors, immunization status,
cultural practices such as circumcision, tattooing and phlebotomy, as well as negative social
behaviors such as intravenous drug use, multiple sex relationships and history of imprisonment
among different age groups in different parts of the world may explain this discrepancy among
different studies.
The overall seroprevalence of 0.1% for HCV noted in our study is almost similar to the pre-
vious reports from Iran, 0.1% in 2003–2005 [18], 0.13% in 2004–2007 [8], 0.17% in 2009 [24],
and 0.11% in 2005–2011 [19]. This prevalence is lower than those of the other countries such
as Pakistan (3.01%-4.99%) [22], Ethiopia (0.7%) [25], China (0.86%) [21], Mongolia (8.7%)
[26], Egypt (5%-25%) [36], Nepal (0.64%) [2], and Nigeria (1.8%) [6] but higher than those of
Mangalore (0.08%) [1], Australia (0.01%) [28], and Italy (0.0016%) [29]. These variations in
prevalence of HCV infection in different parts of the world reflect population risks, health sta-
tus, rates of high-risk behaviors, public awareness, as well as quality of donor screening and
selection procedure in those regions. The highest HCV seroprevalence was observed among
donors aged 20 to 40 years. This can be related to high rate of injecting drug abuse among
youths in Iran. Injecting drug use is the most predominant risk factor for acquiring HCV infec-
tion in our country [9, 17, 18]. Currently, the prevalence of HCV infection among IDUs in Iran
is 50%-75% [9]. Similar results were reported in some previous studies [1–3, 6], while others
have shown higher prevalence among older age groups [4, 21, 35]. This may be due to some
differences in social life styles, level of awareness, predominant routes of transmission, and risk
behavior patterns among different age groups in different parts of the world.
The prevalence of HIV infection among blood donors in our study was reported to be
0.004%, which is lower than those of Mangalore (0.1%) [1], Ethiopia (3.8%) [25], China
(0.31%) [21], Nepal (0.21%) [2], and Nigeria (1.4%) [6] but higher than those of Australia
(0.0003%) [28], Italy (0.00019%) [29], and Mongolia (0%) [26]. These variations in the preva-
lence of HIV might be due to some differences in risk behaviors, educational programs, preven-
tive measures, and quality of safety measures employed in blood transfusion centers of those
countries. The reported prevalence in this study is also in line with the previous reports from
Iran, 0.0054% [19], 0.004% [8, 18].
The seroprevalence of all screened viral infections in this study was lower among female
donors than in male donors. Previous studies have also reported the similar observation in
Fig 1. Trends of HBV, HCV and HIV infections among blood donors in south of Iran, 2004–2014.
doi:10.1371/journal.pone.0157615.g001
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many countries [2, 3, 8, 19, 34, 37]. This might be due to lesser contribution of women in social
activities and high-risk behaviors such as multiple sex relationships and intravenous drug use.
Therefore, these gender differences in infection rates reflect some differences in lifestyles, social
activities, and sexual behavior between these two genders.
The results of the present study in accordance with those of other studies indicate that the
prevalence of viral infections is higher among first-time donors compared to regular and
repeated donors, while regular donors have the lowest frequency of these three pathogens [1, 8,
19, 24, 25]. The reason may be that the regular donors are well-informed individuals with low
risk behaviors due to several time screening and selection in the process of donating blood [1,
5, 19, 21, 25]. Therefore, regular donors should be encouraged to participate more in blood
donation to further improve the safety of blood and reduce the risk of TTIs in the society.
Moreover, in line with the previous studies [19, 24], higher rates of the viral infections were
found among low educated donors in the present study. Better knowledge of highly educated
donors regarding TTIs, their routes of transmission and risk factors can explain this finding.
On the other hand, it is worthy to note that frequently people with lower level of education live
in worse conditions, which increase their vulnerability to infections. Therefore, nationwide
efforts should be made to raise public awareness in people with lower level of education to
reduce the risk of transmission.
This study clearly indicates declining trends in the seroprevalence of HBV and HCV in
donated blood from 2004 to 2014, while HIV had a slight but not significant decline. Similar
decreasing trends have also been reported in previous studies from Iran [8, 17, 18, 20, 24] as
well as some other countries such as Argentina [13], Pakistan [22], Ethiopia [25], Saudi Arabia
[30], Lebanon [38], and Canada [27]. These declining trends might be a reflection of a decline
in the rates of these infections in the society. However, some other factors, including vaccina-
tion against HBV infection, an increase in public awareness regarding general prevalence and
transmission routes of these viral infections, progress in selection of a safer donor population
through application of more standard questionnaire and more effective procedures in physical
examination by trained medical doctors, application of confidential unit exclusion, which
allows self-deferral of high risk donors prior to donation, automation of data registry of all
donors, systematic screening of all donations for infectious markers, improvement in donor
screening procedures through application of more sensitive screening kits, improvement in
safety measures through application of standard instruments and operating procedures, valida-
tion of all procedures across the country, an increase in the number of regular blood donors
from 1716 (14.9%) in 2004 to 19822 (56.6%) in 2014, educational program regarding blood
donation to improve the blood safety, and progress in preventive measures might also explain
such declines in our study.
Despite having common routes of transmission and similar risk factors [6, 35], the preva-
lence of HBV was higher than HCV and HIV in the present study. The similar finding has also
been reported in previous studies from Iran [8, 18, 19]. The reason of this high prevalence may
be higher infectivity of HBV compared to HCV and HIV [34, 39]. Previous studies have also
confirmed this issue [20, 34, 39].
Despite indicating the time trends of these viral infections, a fair comparison between the
years analyzed is not possible, since many factors such as donor selection criteria, sensitivity
and specificity of screening kits used, level of awareness, population risks, behavioral factors,
prevention programs, and the safety measures employed in blood transfusion centers may
change over the years. This is one of the limitations of the current study. Nevertheless, all of
these changes have resulted in a considerable decline in the prevalence of HBV and HCV over
the years.
Viral Infections in Blood Donors
PLOS ONE | DOI:10.1371/journal.pone.0157615 June 16, 2016 15 / 18
Conclusion
The results of the present study confirm the effectiveness of donor screening and selecting policy
employed by IBTO in recent years. Despite these improvements, still a long way is ahead to
achieve a zero-risk blood transfusion. Majority of risks are due to blood donation during the
serologically negative window period or asymptomatic phase of infection as well as the possible
presence of apparently healthy donors with occult infections. During these intervals, blood trans-
fusion is capable of transmitting infection despite negative serological screening tests [1, 9, 30,
39]. Undetectable transmission of viral infections poses a serious threat to blood safety [1, 25].
Fortunately, the most of these unnoticeable transmissions are preventable through application of
nucleic acid-based detection techniques such as polymerase chain reaction (PCR) [21, 30, 37].
The introduction of nucleic acid amplification techniques (NAT) in the realm of diagnosis
of viral infections caused a great revolution in the transfusion medicine. However, PCR is quite
successful in minimizing the threat of unnoticeable infection [37, 40] but is financially and
technically beyond reach of the Iranian blood bank transfusion centers. Currently, routine
screening of blood donations relies on serological tests in Iran [9, 17]. Therefore, it is important
for IBTO to focus on proper selection of donors, continuous screening of donated blood for
infectious markers, and improvement of preventive strategies as well as public awareness to
improve the safety of the blood transfusion in Iran. In addition, rational transfusion of blood
only when necessity arises is also essential to reduce the risk of transmission of these infections
through blood transfusion.
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